Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Growth in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 1,828,008 shares, a growth of 1,667.8% from the August 15th total of 103,406 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 8,029,553 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

XTNT has been the subject of several recent research reports. Loop Capital set a $1.00 target price on shares of Xtant Medical in a research note on Wednesday, September 2nd. BTIG Research restated a “buy” rating and issued a $1.00 price target on shares of Xtant Medical in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $1.00.

Hedge Funds Weigh In On Xtant Medical

A number of hedge funds have recently modified their holdings of XTNT. Jane Street Group LLC acquired a new position in Xtant Medical during the second quarter worth $26,000. Tradition Wealth Management LLC bought a new position in Xtant Medical in the 4th quarter worth approximately $79,000. Wiregrass Investment Management LLC bought a new stake in shares of Xtant Medical in the fourth quarter valued at approximately $81,000. Mink Brook Asset Management LLC boosted its position in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after acquiring an additional 60,997 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Xtant Medical in the fourth quarter worth $220,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Stock Performance

Shares of XTNT traded up $0.01 during trading hours on Thursday, reaching $0.34. 376,122 shares of the company’s stock traded hands, compared to its average volume of 710,290. The firm has a market capitalization of $48.25 million, a price-to-earnings ratio of -4.30 and a beta of -0.15. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.16 and a quick ratio of 1.05. Xtant Medical has a twelve month low of $0.27 and a twelve month high of $0.95. The business’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.47.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). The firm had revenue of $23.03 million during the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.